It used to be that going public was a reason for biotechnology company executives to pop the champagne corks. In years past the goal was to achieve a public listing as quickly as possible in order to first obtain an infusion of cash for product development and then, as a public entity, be in a position to readily access further capital in follow-on offerings. While that goal still remains embedded in the business plans of biotechs, the financial climate that exists today has reduced the urgency for private companies to join the public ranks, and "going public" has become in many ways just another financing event. Read More
The Brain Tumor Awareness Month (BTAM) that runs in May is designed to raise awareness about the serious condition that afflicts approximately 35,000 people each year in the U.S., according to the National Cancer Institute. Glioblastoma multiforme (GBM) is one of the most common and aggressive forms of the disease that progresses rapidly, resulting in poor prognosis for those patients. It represents a significant unmet need and a number of biopharmaceutical companies are developing therapies in that area. Read More